



HOUSE OF REPRESENTATIVES

H. Jt. Res. No. 14

BY REPRESENTATIVES BARBERS, ASISTIO, FUENTEBELLA, ACOP, DEL MAR, GOMEZ, CORVERA, CASTRO (J.),
LUISTRO, OAMINAL, PEÑA, REYES, PADIERNOS AND DELOS SANTOS, PER COMMITTEE REPORT NO. 221

JOINT RESOLUTION

EXTENDING THE LIFE OF THE CONGRESSIONAL OVERSIGHT COMMITTEE ON DANGEROUS DRUGS, CONSTITUTED PURSUANT TO SECTION 95 OF REPUBLIC ACT NO. 9165, AS AMENDED, OTHERWISE KNOWN AS THE “COMPREHENSIVE DANGEROUS DRUGS ACT OF 2002”, TO ANOTHER TEN (10) YEARS FROM JULY 4, 2022 TO JULY 4, 2032

WHEREAS, the Comprehensive Dangerous Drugs Act of 2002 was signed into law on June 7, 2002 as Republic Act No. 9165 and took effect on July 4, 2002;

WHEREAS, pursuant to Section 95 of Republic Act No. 9165, the Congressional Oversight Committee on Dangerous Drugs was constituted upon the effectivity of the Act, composed of seven (7) Members from the House of Representatives and seven (7) Members from the Senate headed by the respective Chairpersons of the House of Representatives Committee on Dangerous Drugs and the Senate Committee on Public Order and Dangerous Drugs;

WHEREAS, Joint Resolution No. 4 was approved by then President Benigno S. Aquino III on August 30, 2012 and extended the life of the Congressional Oversight Committee on Dangerous Drugs from July 4, 2012 to July 4, 2022;

WHEREAS, among the functions of the Congressional Oversight Committee on Dangerous Drugs are the following:

- (a) Set the guidelines and overall framework to monitor and ensure the proper implementation of this Act;
- (b) Ensure transparency and require the submission of reports from government agencies concerned on the conduct of programs, projects and policies relating to the implementation of this Act;
- (c) Approve the budget for the programs of the Congressional Oversight Committee on Dangerous Drugs and all disbursements therefrom, including compensation of all personnel;
- (d) Submit periodic reports to the President of the Philippines and Congress on the implementation of the provisions of this Act;

- (e) Determine inherent weaknesses in the law and recommend the necessary remedial legislation or executive measures; and
- (f) Perform such other duties, functions and responsibilities as may be necessary to effectively attain its objectives;

WHEREAS, the Congressional Oversight Committee on Dangerous Drugs still has to monitor and ensure proper implementation of authorized drug testing, establishment and operation of drug treatment and rehabilitation centers and the joint anti-drug operations of the Philippine Drug Enforcement Agency, the Philippine National Police and the National Bureau of Investigation;

WHEREAS, the Congressional Oversight Committee on Dangerous Drugs has determined inherent weaknesses in the drug law which requires a thorough review of the policies or procedures of implementing agencies, consultations with the judiciary and the codification of the drug law: Now, therefore, be it

1 **RESOLVED BY THE SENATE AND THE HOUSE OF REPRESENTATIVES IN**
2 **CONGRESS ASSEMBLED**, To extend the life of the Congressional Oversight Committee on
3 Dangerous Drugs, constituted pursuant to Section 95 of Republic Act No. 9165, as amended,
4 otherwise known as the “Comprehensive Dangerous Drugs Act of 2002”, to another ten (10) years
5 from July 4, 2022 to July 4, 2032.

Adopted,